Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced two oral presentations on TONMYA (investigated as TNX-102 SL) at the 8th International Congress on Controversies in Fibromyalgia held March 9-10, 2026, in Krakow, Poland. The presentations featured post hoc analyses from the Phase 3 RESILIENT trial and pooled data from the RELIEF and RESILIENT studies, highlighting rapid pain relief and a favorable benefit-risk profile for TONMYA in adults with fibromyalgia.
The data demonstrated statistically significant reductions in pain and a likelihood of clinical benefit nearly four times greater than discontinuation due to adverse events. TONMYA, the first medication approved for fibromyalgia in more than 15 years, was generally well tolerated, with mild and transient oral cavity reactions reported as the most common adverse events. These findings underscore the potential of TONMYA to address a significant unmet medical need in the fibromyalgia community.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the company’s recently approved flagship medicine. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. The company is also evaluating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder.
In addition, Tonix’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. The company is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. For more information, visit the company’s newsroom at https://ibn.fm/TNXP.
The full press release is available at https://ibn.fm/hv3Cl. These presentations at the international congress reinforce the importance of TONMYA as a new treatment option for fibromyalgia, offering hope to patients who have had limited therapeutic choices for over a decade.
